Effectiveness of risk-reducing salpingo-oophorectomy in preventing ovarian cancer in a high-risk French Canadian population

International Journal of Gynecological Cancer

Volumn 22, Issue 6, 2012, Pages 974-978

  Bacha, Omar Moreira ^a   Gregoire, Jean ^b   Grondin, Katherine ^b   Edelweiss, Maria Isabel ^a   Laframboise, Rachel ^b   Simard, Jacques ^b   Plante, Marie ^b  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

BRCA; Ovarian cancer prevention; Prophylactic salpingo oophorectomy; Prophylactic surgery; Risk reducing salpingo oophorectomy

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANADA; CANCER INVASION; CANCER PREVENTION; CANCER RISK; CYSTOSTOMY; FALLOPIAN TUBE ATYPIA; FEMALE; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HEART ARRHYTHMIA; HEMATOMA; HIGH RISK POPULATION; HISTOPATHOLOGY; HUMAN; HYSTERECTOMY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; OVARY CANCER; PERITONEUM CANCER; PREMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCING SALPINGOOOPHORECTOMY; SALPINGOOOPHORECTOMY; UTERINE TUBE DISEASE;

ADULT; AGED; CANADA; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; OVARIECTOMY; OVARY; RETROSPECTIVE STUDIES; SALPINGECTOMY;

EID: 84863632976     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0b013e318257b936     Document Type: Article

References (30)

1. Canadian Cancer Society's Steering Committee. Canadian Cancer Statistics 2010. Toronto, Canada: Canadian Cancer Society; 2010.
2. Easton DF, Deffenbaugh AM, Pruss D, et al. A systematic genetic assessment of 1433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet. 2007;81: 873-883.
3. ACOG Practice Bulletin. Hereditary breast and ovarian cancer syndrome. Gynecol Oncol. 2009;113:6-11.
4. Rutter, JL, Wacholder S, Cherit A, et al. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based casecontrol study. J Natl Cancer Inst. 2003;95:1072-1078.
5. Kauff ND, Barakat RR. Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. J Clin Oncol. 2007;25:2921-2927.
6. Antoniou A, Pharoah PDP, Narod H, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130.
7. Kauff ND, Satagopan JM, Robson ME. Risk-reducing salpingooophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615.
8. Rebbeck TR, Lynch HT, Neuhausen SL. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
9. Nathanson KL, Domchek SM. Therapeutic approaches for women predisposed to breast cancer. Annu Rev Med. 2011;62:21.1-21.12.
10. Kauff ND, Mitra M, Robson ME, et al. Risk of ovarian cancer in BRCA1 and BRCA2 mutation negative hereditary breast cancer families. J Natl Cancer Inst. 2005;97:1382-1384.
11. Olsen JE, Sallers TA, Iturria SJ, et al. Bilateral oophorectomy and breast risk reduction among women with a family history. Cancer Detect Prev. 2004;28:357-360.
12. Simard J, Dumont M, Moisan AM, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet. 2007;44:107-121.
13. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296:185-192.
14. Lu KH, Garber JE, Cramer DH, et al. Occult ovarian tumors in women with BRCA1 or BRCA2 mutations undergoing prophylactic oophorectomy. J Clin Oncol. 2000;18:2728-2732.
15. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23:127-132.
16. Mehrad M, Ning G, Chen EY. A pathologist's road map to benign, precancerous, and malignant intraepithelial proliferations in the fallopian tube. Adv Anat Pathol. 2010;17:293-302.
17. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990.
18. Powell CB, Chen LM, McLennan J et al. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mutation carriers: experience with a consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21:846-851.
19. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002;359:1471-1477.
20. Rebbeck TR, Friebel T, Wagner T, et al. Effect of short-term hormone replacement therapy on breast cancer reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2005;23:7804-7810.
21. Eisen A, Lubinski J, Klijn J, et al. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. J Clin Oncol. 2005;23:7491-7496.
22. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
23. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.
24. ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol. 2008;111:231-241.
25. Kauff ND, Domchek SM, Friebel TM, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26:1331-1337.
26. Garry R, Fountain J, Mason S, et al. The eVALuate Study: two parallel randomised trials, one comparing laparoscopic with abdominal hysterectomy, the other comparing laparoscopic with vaginal surgery. BMJ. 2004;328:129.
27. Lavie O, Ben-Arie A, Gemer O. Possible association between BRCA-1 carriers and incidence of uterine papillary serous carcinoma (UPSC). Int J Gynecol Cancer. 2008;18:1150.
28. Cass I, Holschneider C, Datta N, et al. BRCA-mutation-associated fallopian tube carcinoma: a distinct clinical phenotype? Obstet Gynecol. 2005;106:1327-1334.
29. Duffy S, Jackson TL, Lansdown M, et al; ATAC Trialists' Group. The ATAC adjuvant breast-cancer trial: six-year results of the endometrial subprotocol. J Obstet Gynaecol. 2010;30:596-604.
30. Levine DA, Lin O, Barakat RR, et al. Risk of endometrial carcinoma associated with BRCA Mutation. Gynecol Oncol. 2001;80:395-398.